GB1596476A

GB1596476A - Pyridopyrimidines

Info

Publication number: GB1596476A
Application number: GB22090/78A
Authority: GB
Original assignee: Bristol Myers Co
Current assignee: Bristol Myers Co
Priority date: 1977-05-25
Filing date: 1978-05-24
Publication date: 1981-08-26
Also published as: NL7805534A; AU521211B2; MY8500305A; IT7849523A0; AT365187B; NO150361B; AU3631978A; IT1105040B; NO150361C; DE2822544C2; IE46849B1; YU44212B; YU123678A; FI64594B; SE7805954L; KE3357A; ATA373278A; FI781614A; IE781036L; NL190702B

Description

PATENT SPECIFICATION ( 11) 1 596 476

Q ( 21) Application No 22090/78 ( 22) Filed 24 May 1978 ( 31) Convention Application No 800264 ( 32) Filed 25 May 1977 in es Y 9 b d ( 33) United States of America (US) ( 44) Complete Specification published 26 Aug 1981 ( 51) INT CLU CO 7 D 471/04 A 61 K 31/505 (C 07 D 471/04221/00239/00) I ( 52) Index at acceptance C 2 C 1173 1341 1464 1504 1530 1532 1549 155 X 1562200202213 214 215 220 225 226 22 Y 246 247 250 251 252 255 25 Y 28 X 292 29 X 29 Y 305 30 Y 311 313 314 31 Y 321 322 323 326 32 Y 332 337 338 351 352 355 35 X 35 Y 360 361 362 364 365 366 367 368 36 Y 373 37 Y 386 387 388 397 40 i Y 464 509 50 Y 553 614 620 621 623 624 625 628 633 634 635 652 658 65 X 662 665 670 671 672 675 678 67 X 694 698 761 762 802 80 Y AA LK LY ML QS TR ( 72) Inventor PETER FREDERICK JUBY ( 54) PYRIDO PYRIMIDINES ( 71) We, BRISTOL-MYERS COMPANY, a Corporation organised and existing under the laws of the State of Delaware, United States of America, of 345 Park Avenue, State of New York, 10022, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the 5 following statement:-

This invention relates to optionally substituted 3 (l H tetrazol 5 yl) 4 H pyridoll,2 alpyrimidin 4 one derivatives, processes for their preparation, pharmaceutical compositions containing them and to their use as.

inhibitors of allergic reactions 10 Various medicinal agents have been employed in the treatment of allergic reactions such as bronchial asthma and allergic rhinitis which are believed to result mainly from antigen-antibody interaction With respect to bronchial asthma, one of the most serious of these allergically-mediated diseases, bronchodilators such as theophylline, isoproterenol, epinephrine and atropine are used primarily in 15 providing symptomatic relief These agents, however, have undesirable side effects, e.g cardiac stimulation and gastrointestinal distress.

With the recent introduction of disodium cromoglycate described by J S G.

Cox, etal in Adv in Drug Res,5, 115-196 ( 1970), the physician has been provided with an agent which, when administered to asthmatic patients prior to inhalation of 20 specific antigens, inhibits the release of mediators, e g histamine and SRS-A (slowreacting-substance of anaphylaxis), believed to be responsible for the asthmatic response While making possible a prophylactic treatment for bronchial asthma without cardiovascular side effects and thus representing a significant advance, disodium cromoglycate suffers from a major disadvantage in that it is not orally 25 absorbed and must be administered by inhalation.

With respect to the compounds of the present invention, no examples of tetrazol 5 yl 4 H pyridoll,2 alpyrimidin 4 ones have been found in the literature especially showing antiallergy activity.

The compounds and compositions provided by the present invention are 30 particularly valuable in the prophylactic treatment of allergic bronchial asthma or oral administration.

The antiallergy agents of the present invention may be represented by the formula R 3 N N 2 O K F L I H J wherein RI, R 2, R 3 and R 4 which may be the same or different are each hydrogen.

halogen, (lower)alkyl, cyclo(lower)alkyl, cyclo(lower)alkyl(lower)alkyl.

(lower)alkenyl, (lower)alkynyl, (lower)alkoxy, (lower)alkoxy(lower)alkyl, -O(lower)alkenyl, 5o-0-(CH 2) m CH 2 L) n in which m is 0 or an integer from 1 to 6 and N is an integer from 2 to 7, -OCH 2 (CH 2)x O(CH,),CH 3 in which x and y are each indepjendently 0 or an integer from I to 6, CF 3, hydroxyl hydroxymethyl, (lower)alkylthio, amino, nitro, -If (c Fi 2)r 10 in which r is 4 or 5, -N"', _.

(lower)alkylamino, di(lower)alkylamino, carboxyl, -CO 2 (lower)alkyl, phenyl, phenyl substituted by one or two (lower)alkyl, (lower)alkoxy or halogen radicals, benzyl, (lower)alkylsulfinyl, R CO in which Rc is (lower)alkyl, Rc-COO in 15 which Rc is (lower)alkyl, -O(CH 2)k OH in which k is an integer from 2 to 6, -OCH 2 CH-CH 2 OH, -OCH 2-CH-CH 2 OCH 3 or -OCH 2 C 6 Hs, I I OH OH or R 2 and R 3 or R 3 and R 4 when taken together are methylenedioxy or 9 E Hz)n in which N is 3, 4 or 5, and pharmaceutically acceptable salts thereof 20 The R', R 2, R 3 and R 4 substituent groups disclosed above may be further defined as follows:

(a) By "halogen" is meant chlorine, bromine, fluorine and iodine; (b) By "(lower)alkyl" is meant both straight and branched chain saturated aliphatic hydrocarbon radicals having from I to 6 carbon atoms inclusive, e g 25 methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tertbutyl, n-pentyl, isopentyl, and n-hexyl.

(c) By "(lower)alkenyl" is meant straight or branched unsaturated aliphatic hydrocarbon radicals containing one double bond and having from 2 to 6 carbon atoms inclusive, e g vinyl, allyl, isopropenyl, 2 or 3-methallyl or 3butenyl; 30 (d) By "(lower) alkoxy" is meant C,-C, alkoxy radicals, the alkyl portion of such radicals being defined as in (b) above Examples include methoxy, ethoxy, npropoxy, iso-propoxy, n-butoxy, isobutoxy, sec-butoxy, n-pentyloxy, isopentyloxy, and n-hexyloxy.

(e) -O-(lower)alkenyl groups are radicals in which the alkenyl portion is as 35 defined above in (c), e g vinyloxy, allyloxy or isopropenyloxy; (f) -O-(CH)=CYF(CH 2)n represents cyclo(lower)alkyloxy and cyclo(lower)alkyl-(C, C 6)alkyloxy groups in which the cycloalkyl ring contains from 3 to 8 carbon atoms, preferably 3 to 6 40 carbon atoms Examples of such groups are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, cyclopropylmethyloxy, cyclopropylethyloxy, cyclobutylmethyloxy, cyclobutylethyloxy, cyclopentylmethyloxy, cyclohexylmethyloxy, cyclohexylethyloxy and cyclohexylpropyloxy; 45 1,596,476 (g) -O 0-CH 2 (CH 2)x O(CH 2),CH 3 represents radicals such as -OCH 20 CH 3, -OCH 2 CH 20 CH 3, -OCH 2 CH 20 CH 2 CH 3, -OCH 2 OCH 2 CH 3 and -OCH 2 CH 2 CH 2 OCH 2 CH 3; (h) By "(lower)alkylthio" is meant C,-C 6 alkylthio radicals in which the alkyl portion is as defined above in (b) Examples of such groups are methylthio, 5 ethylthio, n-propylthio and n-butylthio; (i) By "(lower)alkylamino" is meant C 1-C 6 alkylamino radicals in which alkyl is as defined in (b) Examples of such groups are methylamino, ethylamino, propylamino and butylamino; (j) By "di(lower)alkylamino" is meant di C,-C 6 alkylamino radicals in which 10 alkyl is as defined above in (b) Examples of such groups are dimethylamino and diethylamino; (k) By "-CO 2-(lower)alkyl" is meant ester radicals in which the alkyl moiety is as defined above in (b), e g carbomethoxy, carbethoxy, carbopropoxy and carbobutoxy; 15 (I) By "(lower)alkylsulfinyl" is meant radicals of the formula 0 11 -S-(lower)alkyl in which the alkyl portion is as defined above in (b) Examples of such radicals include methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, nbutylsulfinyl, sec-butylsulfinyl, isobutylsulfinyl, t-butylsulfinyl, npentylsulfinyl and 20 n-hexylsulfinyl The most preferred alkylsulfinyl group is methylsulfinyl; (m) Acyl includes radicals of the type Rc-CO where Rc is (lower alkyl), e g.

CHACO-, C 2 Hs CO-, C 3 H 7 CO; (n) Acyloxy includes radicals of the type Rc-COO in which Rc is (lower)alkyl Examples are CH 3 COO-, C 2 Hs COO-, C 3 H 7 COO-; 25 (o) (o) represents pyrrolidino and piperidino; (p) By "cyclo(lower)alkyl" is meant cycloalkyl radicals having from 3-6 carbon atoms Examples include cyclopropyl, cyclobutyl and cyclohexyl 30 (q) R 2 and R 3, or R 3 and R 4 taken together may be CH 2)n which represents a saturated five, six or seven membered monocyclic hydrocarbon radical fused to the A ring of the pyridoll,2-alpyrimidine ring system, e g.

N-N A BJ N A B / N or 35 n = 4 N = 3 (r) By "(lower)alkynyl" is meant straight or branched unsaturated aliphatic hydrocarbon radicals containing one triple bond and having from 2 to 6 carbon atoms inclusive, e g ethynyl, propargyl,-butynyl, pentynyl or-hexynyl; (s)'By "lower)alkoxy (lower)alkyl" is meant radicals where the (lower) allkoxy and (lower)alkyl portions are as defined above in (d) and (b), respectively, e g 40 methoxymethyl, methoxyethyl, ethoxymethyl, ethoxyethyl, and methoxypropyl, and 1,596,476 (t) By "cyclo(lower)alkyl(lower)alkyl" is meant radicals in which the cyclo(lower)alkyl and (lower)alkyl portions are as defined above in (p) and (b) respectively, e g cyclopropylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclohexylmethyl, and cyclohexylethyl.

A preferred embodiment of the present invention comprises the compounds of 5 formula I wherein R', R 2, and R 3 and R 4 which may be the same or different are each hydrogen, (lower)alkyl, (lower)alkenyl, (lower)alkoxy, hydroxy, carboxy, (lower)alkylthio, halogen, CF 3, amino, (lower)alkylamino, di(lower) alkylamino, phenyl or benzyl.

A more preferred embodiment of the present invention comprises the 10 compounds of the formula R 1 N N 7 H R 2 78 j ' I ' R 3/9 1 ' R wherein R 1, R 2 and R 3 which may the same or different are each hydrogen, halogen, (lower)alkyl, cyclo(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, (lower)alkenyl, (lower)alkynyl, (lower)alkoxy, (lower)alkoxy(lower)alkyl, -O 15 (lower)alkenyl, ,-, ('2 my&c 2)n in which m'is 0 or an integer from I to 6 and N is an integer from 2 to 7, -OCH 2 (CH 2)x O(CH 2)y CH 3 in which x and y are each independently 0 or an integer from I to 6, CF 3, hydroxy, 20 hydroxymethyl, (lower)alkylthio, amino, nitro, xy 2) r in which r is 4 or 5, (lower)alkylamino, di(lower)alkylamino, carboxyl, -CO 2-(lower)alkyl, phenyl, 25 phenyl substituted by one or two (lower)alkyl, (lower)alkoxy or halogen radicals, benzyl, (lower)alkylsulfinyl, Rc-CO in which Rc is (lower)alkyl, Rc-COO in which Rc is (lower)alkyl, -O(CH 2)k OH in which k is an integer from 2 to 6, -OCH, CH-CH 2 OH, -OCH 2-CH-CH 2 OCH 3 or -OCH 2 C 6 Hs, I I OH OH or wherein any two of R', R 2 and R 3 at positions 7 and 8 or 8 and 9 of the 30 pyridoll,2-alpyrimidine ring system when taken together represent methylenedioxy or SCH 2) n in which N is 3, 4 or 5, and the pharmaceutically acceptable salts thereof Within this group of compounds, a preferred subgroup comprises those compounds where 35 R', R 2 and R 3 are each independently hydrogen, (lower)alkyl, (lower) alkenyl, (lower)alkoxy, hydroxy, carboxy, (lower)alkylthio, halogen, CF 3, amino, (lower)alkylamino, di(lower)alkylamino, phenyl or benzyl The RI, R 2 and R 3 substituents of compound 1 ' may be located at any of positions 6, 7, 8 or 9 of the pyridoll,2-alpyrimidine ring system as numbered above 40 1.596,476 Another more preferred embodiment of the present invention comprises the compounds of the formula N N R 1 o 11 11 i R 2 " '' wherein R' and R 2 which may be the same or different are each hydrogen, halogen, (lower)alkyl, cyclo(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, (lower) alkenyl, 5 (llower)alkynyl, (lower)alkoxy, (lower)alkoxy(lower)alkyl, -O-(lower) alkenyl, O-(Ca 2)mc,-YCH 2)n in which m is 0 or an integer from I to 6 and N is an integer from 2 to 7, -OCH 2 (CH 2)XO(CH 2)y CH 3 in which x and y are each independently 0 or an integer from I to 6, CF 3, hydroxy, 10 hydroxymethyl, (lower)alkylthio, amino, nitro, -Ur(Cl) r in which r is 4 or 5, (lower)alkylamino, di(lower)alkylamino, carboxyl, -CO 2 (lower)alkyl, phenyl, 15 phenyl substituted by one or two (lower)alkyl, (lower)alkoxy or halogen radicals, benzyl, (lower)alkylsulfinyl, Rc-CO in which Rc is (lower)alkyl, Rc-COO in which Rc is (lower)alkyl, -O(CH 2)k OH in which k is an integer from 2 to 6, -OCH 2-CH-CH 2 OH, -OCH 2-CH-CH 2 OCH 3 or -OCH 2 C 6 Hs, l l OH OH or R' and R 2 when taken together at positions 7 and 8 or 8 and 9 of the pyridoll,2 20 alpyrimidine ring system are methylenedioxy or \ 3 SCH 2) n in which N is 3, 4 or 5, and the pharmaceutically acceptable salts thereof Within this group of compounds, a preferred subgroup comprises those compounds wherein R' and R 2 are each independently hydrogen, (lower)alkyl, (lower) alkenyl, 25 (lower)alkoxy, hydroxy, carboxy, (lower)alkylthio, halogen, CF 3, amino, (lower)alkylamino, di(lower)alkylamino, phenyl or benzyl The R' and R 2 substituents of compound I" may be located at any of positions 6, 7, 8 or 9 of the pyridol I,2-alpyrimidine ring system.

Another more preferred embodiment of the present invention comprises the 30 compounds of the formula N N I'' ' H 1,596,476 wherein RI and R 2 which may be the same or different are each hydrogen, halogen, (lower)alkyl, cyclo(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, (lower)alkenyl, (lower)alkynyl, (lower)alkoxy, (lower)alkoxy(lower)alkyl, -O(lower)alkenyl, _o (cr 2) c mca,c HF F)5 in which m is 0 or an integer from I to 6 and N is an integer from 2 to 7, -OCH 2 (CH 2)x O(CH 2),CH 3 in which x andy are each independently 0 or an integer from I to 6, CF 3, hydroxy, hydroxymethyl, (lower)alkylthio, amino, nitro, -r T(CF 2) 10 o in which r is 4 or 5, _N-'8 '.

(lower)alkylamino, di(lower)alkylamino, carboxyl, -C 02-(lower)alkyl, phenyl, phenyl substituted by one or two (lower)alkyl, (lower)alkoxy or halogen radicals, benzyl (lower)alkylsulfinyl, Rc CO in which Rc is (lower)alkyl, Rc COO in 15 which Rc is (lower)alkyl, -O(CH 2)k OH in which k is an integer from 2 to 6, -OCH 2-CH-CH 2 OH, -OCH 2-CH-CH 2 OCH 3 or -OCH 2 C 6 Hs, I I OH OH or R' and R 2 when taken together at positions 8 and 9 of the pyridofl 1, 2alpyrimidine ring system are methylenedioxy or (Cl) 20 in which N is 3, 4 or 5, and the pharmaceutically acceptable salts thereof Within this group of compounds, a preferred subgroup comprises those compounds wherein RI and R 2 are each independently hydrogen, (lower)alkyl, (lower) alkenyl, (lower)alkoxy, hydroxy, carboxy, (lower)alkylthio, halogen, CF 3, amino, (lower)alkylamino, di(lower)alkylamino, phenyl or benzyl The R 2 substituent of 25 compound I"' may be located at any of positions 6, 7 or 8 of the pyridol 1,2alpyrimidine ring system.

Another more preferred embodiment of the present invention comprises the compounds of the formula 0 2 1 N H 30 wherein RI and R 2 which may be the same or different are each hydrogen, halogen.

(lower)alkyl, cyclo(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, (lower) alkenyl, (lower)alkynyl, (lower)alkoxy, (lower)alkoxy(lower)alkyl, -O-(lower) alkenyl, -o (CH)m CF -(c H),n in which m is 0 or an integer from I to 6 and N is an integer from 2 to 7, 35 -OCH 2 (CH 2),O(CH 2),CH 3 1,596,476 1,596,476 in which x and y are each independently 0 or an integer from I to 6, CF 3, hydroxy, hydroxymethyl, (lower)alkylthio, amino, nitro, -n (Ch) r in which r is 4 or 5, (lower)alkylamino, di(lower)alkylamino, carboxyl, -CO 2-(lower)alkyl, phenyl, phenyl substituted by one or two (lower)alkyl, (lower)alkoxy or halogen radicals, benzyl, (lower)alkylsulfinyl, Rc-CO in which Rc is (lower)alkyl, Rc-COO in which Rc is (lower)alkyl, -O(CH 2)k OH in which k is an integer from 2 to 6, -OCH 2-CH-CH 2 OH, OH -OCH 2 CH-CH 2 OCH 3 or -OCH 2 C 6 Hs, OH OH and the pharmaceutically acceptable salts thereof Within this group of compounds, a preferred subgroup comprises those compounds wherein R' and R 2 are each independently hydrogen, (lower)alkyl, (lower)alkenyl, (lower) alkoxy, hydroxy, carboxy, (lower)alkylthio, halogen, CF 3, amino, (lower) alkylamino, di(lower)alkylamino, phenyl or benzyl.

Another more preferred embodiment of the present invention comprises the compounds of the formula :1.

R I '''' H wherein R 1 is hydrogen, halogen, (lower)alkyl, cyclo(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, (lower)alkenyl, (lower)alkynyl, (lower) alkoxy, (lower)alkoxy(lower)alkyl, -O (lower)alkenyl, -o 2) ( c" z CF i)n in which m is 0 or an integer from I to 6 and N is an integer from 2 to 7, -OCH 2 (CH 2)XO(CH 2)y CH 3 in which x andy are each independently 0 or an integer from I to 6, CF 3, hydroxy, hydroxymethyl, (lower)alkylthio, amino, nitro, in which r is 4 or 5, in which r is 4 or 5, (lower)alkylamino, di(lower)alkylamino, carboxyl, -CO 2 (lower)alkyl, phenyl, phenyl substituted by one or two (lower)alkyl, (lower)alkoxy or halogen radicals, benzyl, (lower)alkylsulfinyl, R-CO in which RC is (lower)alkyl, Rc-COO in which RC is (lower)alkyl, -O(CH 2)k OH in which k is an integer from 2 to 6.

-OC H 2-C-H-CH OH, OH -OCH 2-CH-CH 2 OCH 3 -or -OCH 2 C Hs,.

OH and the pharmaceutically acceptable salts thereof Within this group of 8 1 596476 compounds, a preferred subgroup comprises the compounds wherein r' represents hydrogen, (lower)alkyl, (lower)alkenyl, (lower)alkoxy, hydroxy, carboxy, (lower)alkylthio, halogen, CF 3, amino, (lower)alkylamino, di(lower) alkylamino, phenyl or benzyl.

While the R' substituents in the compounds of formula I""' may be located at 5 any of positions 6, 7, 8 or 9 of the pyridol 1,2-alpyrmidine ring system, the 6-, 7 and 9-substituted compounds are preferred The most preferred monosubstituted compounds are those having the substituent at the 9-position.

Since the compounds of this invention are amphoteric in nature, they can be converted to salts of either acids or bases by treating said compounds with a 10 substantially equimolar amount of a chosen acid or base in an aqueous solution or in a suitable organic solvent such as methanol or ethanol When such salts are to be used for human consumption, the acids or bases-which are used to prepare the pharmaceutically acceptable salts must, of course, be those which necessarily form non-toxic salts Examples of suitable acids include hydrochloric, hydrobromic, 15 hydroiodic, nitric, sulfuric, phosphoric, acetic, lactic, citric, tartaric, oxalic, succinic, maleic, gluconic, ascorbic and p-toluene sulfonic Pharmaceutically acceptable salts may be formed from such bases as ammonia, organic amines and metal salts, e g metal salts containing sodium, potassium, calcium, magnesium, barium and aluminum cations Representative of such bases are ammonia, primary 20 amines such as n-propylamine, n-butylamine, ethanolamine, ethylenediamine, cyclohexylamine, benzylamine, ethylamine, octylamine or tris(hydroxymethyl)aminomethane, secondary amines such as diethanolamine, tertiary amines such as triethanolamine, N-methylpyrrolidine Nmethylmorpholine, or 1,5-diazabicyclol 4,3,0 l-5-nonene and metal compounds such 25 as sodium hydroxide, potassium hydroxide, ammonium hydroxide, sodium ethoxide, potassium methoxide, magnesium hydroxide, calcium hydroxide or aluminum hydroxide.

Those skilled in the art will appreciate that the compounds represented by formulae I-I""' contain a tautomeric hydrogen atom and the compounds are thus 30 capable of existing in the 1 H-tetrazol-5-yl form (see formula 1 S below) and the 2 Htetrazol-5-yl form (formula lb below).

N N R,r N X 95 N I Ib a This invention embraces both forms, but for the sake of convenience, structure Ia has been arbitrarily selected to describe the present compounds 35 The compounds of the present invention may be prepared by the methods set forth below.

One preferred method comprises reacting a nitrile of the formula R 2 A J W CN R 3 II (wherein R', R 2, R 3 and R 4 are defined as above in reference to formula I) with an 40 azide salt selected from the group consisting of ammonium, substituted ammonium and sodium and lithium azide in an inert organic solvent The nitrile 11 and azide salt may be used in approximately equimolar amounts The general conversion of nitriles to tetrazoles is described by W G Finnegan, et al in J Am Chem Soc 80, 3908 ( 1958) Examples of suitable azide salts for this process are provided by 45 1.596476 R Finnegan in the above-mentioned reference and includes azides such as Na N 3, Li N 3, NH 4 N 3, (n-C 4 Hg)2 NH 2 N 3, C 6 Hs NH 3 N 3 and (CH 3)4 NN 3 The azide salt may be added directly or may be generated in situ, e g by double decomposition reactions of sodium azide and an appropriate chloride salt such as Li CI, NH 4 CI, (CH 3)4 NCI, etc While the condensation reaction proceeds over a wide temperature range, it is 5 preferred in order to minimize reaction times to use elevated temperatures, e g.

from about 100 C up to the reflux temperature of the solvent system The inert organic solvent may in general be any solvent having good power for the azide salt and which is chemically inert Examples of preferred solvents are dimethylformamide, dimethylacetamide, dimethylsulfoxide and 10 hexamethylphosphoramide The most preferred solvent is dimethylformamide The condensation reaction is found to be subject to general acid catalysis and yields are improved by addition of such reagents as hydrazoic acid, amine hydroazides and Lewis acids such as BF 3 to the sodium azide At the completion of the reaction, the tetrazole product may be recovered from the reaction mixture by removing the 15 solvent, diluting the residue with water and then acidifying the mixture to give the desired product of formula I The product may be further purified by recrystallization and optionally converted to a pharmaceutically acceptable salt thereof as described above Following condensation, products of formula I may, if desired, be further reacted by methods known per se to convert one or more RI, R 2, 20 R 3 or R 4 substituent groups to other substituent groups within the scope of formula I Thus, for example, a compound of formula I having a nitro substituent may be subjected to catalytic hydrogenation to give the corresponding amino substituted compound or a compound having an amino substituent may be alkylated to give the corresponding (lower)alkylamino or di(lower)alkylamino-substituted compound 25 An alternative and preferred variation of the above procedure involves condensing the nitrile starting material II with aluminum azide in tetrahydrofuran followed by an acidification recovery step as described above The reaction may conveniently be carried out by reacting nitrile II with aluminum chloride and sodium azide in molar proportions of about 1:1 3, respectively While the 30 temperature for this reaction is not critical,' advantageous results have been obtained at the reflux temperature of the solvent.

Another alternative variation of the above procedure comprises heating the desired nitrile compound II with either hydrazoic acid in an inert organic solvent such as benzene, xylene or toluene or with sodium azide and acetic acid in butanol 35 In this procedure an acidification step is not required to recover the desired endproduct.

An alternative and most preferred procedure for preparing the compounds of formula I comprises reacting an acrylate intermediate of the formula R 1 R 3 VI '40 R NHCH=C(CN)C O 02 C 2 H 5 (wherein R', R 2, R 3 and R 4 are as defined above in reference to formula 1) with aluminum azide in tetrahydrofuran The preferred reaction conditions, i e molar ratios and temperature ranges, are as described above in connection with the nitrile to tetrazole conversion with AI(N 3)3 The product of formula I may be conveniently recovered from the reaction mixture by addition of sufficient water followed by 45 acidification to effect precipitation of the desired compound I The tetrazole product I may, if desired, be subsequently converted as discussed above to a pharmaceutically acceptable salt or to another product of formula I having different R', R 2, R 3 or R 4 substituents.

Another preferred procedure for preparing the compounds of formula I 50 comprises reacting a 2-aminopyridine of the formula 1,596,476 1596476 a Il R 3 VII NH 2 R (wherein R', R 2, R 3 and R 4 are as defined above in reference to formula I) with ethyl ethoxymethylenecyanoacetate of the formula C 2 Hs CH=C(CN)CO 2 C 2 Hs VIII and aluminum azide in tetrahydrofuran Approximately equimolar quantities of the three reactants are used, and the aluminum azide may be conveniently prepared in situ by reaction of sodium azide and aluminum chloride in molar proportions of about 3:1, respectively For best results, the reaction is carried out at the reflux temperature of the solvent At the conclusion of the reaction, the desired product can be recovered by addition of sufficient water followed by acidification to precipitate compound I from the reaction mixture The product may as described above be further reacted to produce a pharmaceutically acceptable salt thereof or another product of formula I having different R', R 2, R 3 or R 4 substituents.

The above process is a preferred embodiment of the present invention since it enables compound I to be prepared directly from the basic 2-aminopyridine and ethyl ethoxymethylenecyanoacetate starting materials without the necessity of first preparing and isolating one or more intermediates required for the alternative methods described above.

The nitriles starting materials of formula II may be prepared by known reaction routes One reaction scheme is indicated below:

C 2 H 502 C c Hszac b CO 2 C H + 2 c C 2 H 5 Q 2 22 2 50"", H 3 II CH \ H R i t N H /1 H IX R inert solvent, A or polyphosphoric acid (PPA CO 2 C 2 H 5 liquid NH 3 sealed vessel, steam bath CO 2 C 2 H CONH 2 III IV dehydrating agent, e.g POC 13 / R 1 R 32 " CN R 4 II N VII R 3 1.596 476 In The 2-aminopyridine starting materials of formula VII are known compounds or are prepared by methods well known in the art.

Condensation of 2-aminopyridines (formula VII) with diethyl ethoxymethylenemalonate (formula IX) to produce the esters of formula IV is welldocumented in the literature (see prior art section above and, in particular U S 5

Patent 3,585,198, J Chem Soc (C), 2735 ( 1971), J Org Chem, 33, 3015 ( 1968), Arzneim -Forsch, 22, 815 ( 1972) and J Amer Chem Soc, 70, 3348 ( 1948), and the references cited therein).

Amide intermediates of formula III may be obtained by treatment of the esters of formula IV with liquid ammonia, ammonium hydroxide or a solution of ammonia 10 in a (lower)alkanol (e g methanol or ethanol) optionally containing sodium methoxide as a catalyst The reaction is conveniently carried out in a sealed vessel at steam bath temperature When concentrated ammonium hydroxide is used, good results have also been achieved at room temperature for one to two days without the necessity of either heat or a sealed vessel 15 The amide intermediates of formula III may be converted to the nitriles of formula II by use of a dehydrating agent such as phosphorus pentoxide, thionyl chloride, p-toluenesulfonyl chloride:pyridine or, most preferably, phosphorus oxychloride Dehydration is accomplished at elevated temperatures, most preferably under reflux conditions 20 The acrylate starting materials of formula VI may be prepared by condensing approximately equimolar amounts of a 2-aminopyridine compound of formula VII with ethyl ethoxymethylenecyanoacetate in the presence or absence of an inert organic solvent, e g an aromatic hydrocarbon such as toluene The reaction is preferably carried out at elevated temperatures, e g 100 C Some examples of the 25 acrylates of formula VI (i e when the pyridine ring is unsubstituted or substituted at the 3-, 4 or 6-position by methyl) are disclosed by Antaki in J Amer Chem Soc, 80, 3066 ( 1958) and by Nishigaki, et al in J Heterocycl Chem, 8, 759 ( 1971).

In using the above-described processes to prepare compounds of formula I in which RI, R 2, R 3 and R 4 contain free hydroxy, amino or carboxyl groups, it is of 30 course understood that such groups will be protected by suitable known protecting groups during the reaction steps beginning with the basic 2-aminopyridine starting materials through the formation of the final tetrazoles The protecting group(s) may then be removed by methods known per se to give the desired products having the unprotected substituent groups Amino-substituted compounds may be prepared 35 from the corresponding nitro-substituted product by catalytic hydrogenation In preparing compounds of formula I where R', R 2, R 3 or R 4 are (lower) alkylamino or di(lower)alkylamino, the corresponding amino-substituted compound may first be prepared and then alkylated Alternatively, the dialkylamino-substituted compounds can be prepared directly from the appropriate 2-amino-pyridine 40 starting material.

In another aspect of the present invention, there is provided a method of inhibiting or preventing the symptoms of an allergic reaction such as allergicbronchial asthma or allergic rhinitis in a non-human mammal susceptible to such a reaction which comprises administering to said mammal a prophylactically 45 effective dose of a compound of formula I or a pharmaceutically acceptable salt thereof.

The compounds of the present invention may be administered either as individual therapeutic agents or as mixtures with other therapeutic agents They may be administered alone but are generally administered in the form of 50 pharmaceutical compositions, i e mixtures of the active agents with suitable pharmaceutical carriers or diluents Examples of such compositions include tablets, lozenges, capsules, powders, aerosol sprays, aqueous or oily suspensions, syrups, elixers and aqueous solutions The compounds are preferably administered orally, but may also be administered by inhalation, injection, instillation or by 55 implantation for controlled drug release from a solid carrier reservoir.

The nature of the pharmaceutical composition and the pharmaceutical carrier or diluent will, of course, depend on the desired route of administration For example, oral compositions may be in the form of tablets or capsules and may contain conventional excipients such as binding agents (e g syrup, acacia gelatin, 60 sorbitol, tragacanth or polyvinylpyrrolidone), fillers (e g lactose, sugar, maizestarch, calcium phosphate, sorbitol or glycine), lubricants (e g magnesium stearate, talc, polyethylene glycol, or silica), disintegrants (e g starch) or wetting agents (e g sodium lauryl sulfate) Oral liquid preparations may be in the form of aqueous or oily suspensions solutions, emulsions, syrups, elixers, etc or may be 65 l l 1,596,476 l l presented as a dry product for reconstitution with water or other suitable vehicle before use Such liquid preparations may contain conventional additives such as suspending agents, flavoring agents, diluents or emulsifying agents For parenteral administration, inhalation or instillation, solutions or suspensions of a compound of formula I with conventional pharmaceutical vehicles may be employed, e g as an 5 aerosol spray for inhalation, as an aqueous solution for intravenous injection or instillation, or as an oily suspension for intramuscular injection The compounds may also be administered by means of inhalers or other devices which permit the active compounds in the form of dry powders to come into direct contact with the lungs 10 The compounds of the present invention or pharmaceutical compositions thereof may be administered to human allergic patients in single oral doses of approximately 0 05-500 mg of active ingredient and multiple oral doses totalling up to about 1000 mg /day of active ingredient When administered by inhalation or instillation, lower doses are generally given, i e on the order of about 0 1 of the 15 normal oral dosage for the particular compound in question These values are illustrative only, however, and the physician of course will ultimately determine the dosage most suitable for a particular patient on the basis of factors such as age, weight, severity of the symptoms and the particular agent to be administered.

The in vivo animal model studies described below indicate that the compounds 20 of formula I are highly potent antiallergy agents.

Biological Activity Data The reagin-mediated rat Passive Cutaneous Anaphylaxis (PCA) screening test used to evaluate the present compounds is generally regarded as one of the best animal models for use in predicting the antiallergy activity of test compounds in 25 man Briefly, the method consists of passive sensitization of skin sites on the test animals with reaginic antibodies followed after 24 hours by administration of the test drug and antigen challenge The allergic response is measured by use of Evans' blue dye and is evaluated by the spot diameter at the injection site Details of the test are provided below 30 Materials Ovalbumin ( 5 times crystalline) Dinitrobenzene sulfonic acid, Na+ salt Bordetella pertussis vaccine-phase I 10-20 x 109 killed organisms/ml.

Aluminum hydroxide gel-10 mg /ml 35 Potassium carbonate Male Sprague-Dawley (S/D) Rats-200 gins.

Female Spraque-Dawley Rats-100 gins.

Tris Buffered Saline (TBS)-0 02 M 2-amino-2-hydroxymethyl-l,3propanediol (Tris), 0 15 M Na CI, p H 8 2 40 Antigen Preparation-DNP-d EA A substituted ovalbumin antigen is used both as immunogen and challenging antigen The antigen is prepared as follows: 500 mrg, ovalbumin (EA) and 500 mg.

K 2 CO 3 are dissolved in 25 ml distilled H 20 and stirred at room temperature for 5 minutes Five hundred ( 500) mrg dinitrobenzene sulfonic acid, Na+ salt, (previously 45 recrystallized from hot absolute ethanol) is then added slowly with continued stirring The reaction mixture is then immediately placed in the dark and allowed to proceed for 2 hours with constant stirring After 2 hours the mixture is placed in suitable dialysis tubing and dialyzed against 5 changes ( 4 liters each) of distilled H 20 at 5 C After dialysis the product is lyophilized and stored at room 50 temperature in a brown or amber container The antigen obtained will appear as a light yellow, amorphous solid which is very soluble in water or saline It is designated as DNP denatured ovalbumin (DNP-d EA).

Immunization Method for Ig E Production Adult, male Spraque-Dawley rats are used as a source of reagin-rich antisera 55 for the PCA model Immunization is by a combination of DNP-d EA on AI(OH)3 gel and B pertussis vaccine Preparation of the DNP-d EA-gel immunogen is as follows: Dissolve the DNP-d EA in TBS so as to give a concentration of 10 mg /ml.

Slowly add I ml of this solution to 10 ml AI(OH)3 gel ( 10 mg solids/mi) with 1,596476 constant stirring at room temperature Stir the mixture an additional 30 minutes to insure a uniform adsorption of antigen on gel.

The resulting preparation is then used in combination with phase I B pertussis vaccine to immunize male S/D rats as follows: For each rat administer 0 1 ml DNPd EA-gel suspension intramuscularly in each hind leg ( 200 /g DNP-d EA and 2 5 mg gel total dose) Follow these injections by the intraperitoneal administration of 1.0 ml B pertussis vaccine ( 10-20 x 109 organisms) The use of light ether anesthesia during this procedure is recommended to insure proper intramuscular and intraperitoneal injections Nine days following immunization (but no longer than 10) the animals are exsanguinated by cardiac puncture or abdominal aorta 10 cannulation under ether or pentobarbital anesthesia The collected whole blood is allowed to clot, the serum separated by centrifugation and the individual serum samples stored frozen until assayed for Ig E content.

Selection of High Titered Serum Samples for Pooling Individual serum samples should be screened for reaginic antibody 15 concentration before being pooled with other sera, as not all rats respond to immunization procedures with reagin production A 1:50 saline dilution of serum from each immunized rat is used for this purpose Intradermal injections of 0 05 ml.

of the diluted sera are made in the shaven backs of two small female recipient rats, 100-120 gms Several serum samples can be tested simultaneously in recipient 20 animals After a 24 to 48 hour latent period antigen challenge is accomplished by intravenous administration to each rat of I mg DNP-d EA in 0 5 ml 0 5 % Evans' blue dye in saline Sera which show positive PCA reactions at the 1:50 dilution, as measured 20 to 30 minutes post-challenge are pooled, dispensed in small aliquots and stored at -70 C or lower until used Negative sera may be discarded 25 The Ig E titer of the antisera pool should then be determined Serial twofold dilutions ( 1:5 to 1:160) of unheated sera and sera heated at 56 C for 1 hour are prepared in saline and 0 05 ml of each dilution injected intradermally on the backs of female recipient rats At least four animals should be used for both the heated and unheated serum titrations After a 24-hour latent period each group is 30 challenged with I mg DNP-d EA in 0 5 ml 0 5 % Evans' blue dye Reactions are read by reflecting the skin 20 to 30 minutes post-challenge Intensity (blueing) and spot diameter should be measured and recorded The pool titer is defined as the reciprocal of the greatest dilution of unheated serum which yields a measurable PCA response (> 6 mm diameter) in at least half of the recipient animals 35 Antiserum pools having a titer of 50 or greater are acceptable for the PCA screen.

These pools should be sterile-filtered and stored at -70 C or lower until use.

Lyophilization in small aliquots may be used as an alternate.

PCA Screening Method 1 Animals-Young female Sprague-Dawley rats, 90-110 gms should be 40 used The rats should be conditioned (acclimatized) for at least five days prior to use, with food and water ad lib.

2 Passive Sensitization-The test animals are prepared for passive sensitization by carefully shaving areas on each side of the back with a fine toothed clipper Using a 27 gauge 5/8 " needle mounted on a I ml tuberculin syringe make 45 intradermal injections of saline dilutions of the antiserum pool Four dilutions (two on either side) of antiserum are used The exact dilutions used depend on the titer of the pool For example, if the antiserum pool has a titer of 50, then dilutions of 1:10, 1:20, 1:30 and 1:40 are used; if the pool titers at 100, then the dilutions would be 1:20, 1:40, 1:60 and 1:80 The sequence of placement of each dilution should be 50 either clockwise or counter-clockwise to facilitate ease in scoring The latent period should be at least 24 but not more than 48 hours.

3 Drug Administration-Standard and Unknowns-Four animals are used for each test compound Disodium cromoglycate (DSCG), solubilized in saline, is administered by intravenous (i v) route at the time of antigen challenge The 55 tetrazole test compounds are solubilized in aqueous sodium bicarbonate The test compounds are administered i v or per os (p o) either 1-5 or 10 minutes,:

respectively prior to antigen challenge.

4 Antigen Challenge and Reaction Evaluation-Elicitation of the PCA response is accomplished by intravenous administration of I mg DNP-d EA in 0 5 60 ml 0 5 % Evans' blue dye in saline to each test rat PCA reactions are maximal twenty to thirty minutes post-challenge Reactions should be scored visually for color intensity and the average diameter of the spots measured at each antiserum 1,596,476 dilution site Both operations should be done by reflecting the skin For comparative purposes the numbers in the control group (untreated) should be at least 5 % and usually 10 %, of the total animals tested on a particular day.

Observed drug inhibition is reported as perccnt reduction in effective antiserum titer in treated versus control groups.

Results Test results for certain of the preferred compounds of the present invention by i.v and p o routes of administration are shown below in Table I along with data for DSCG The results are given in terms of the I Dso value, i e the dose of compound that inhibits 50 % of the response 10 TABLE I -

Rat PCA Screening Data for 3-(IH-tetrazol-5-yl)4 H-pyridol 1,2-alpyrimidin-4-ones Compound 15 R Example I Dso in mg /kg.

No R 1 R 2 R 3 R 4 i v p o.

1,2,3 H H H H 0 06 -0 1 4 H CH 3 H H -0 1 5 H H CH 3 H 2 4 20 6 H CH 3 CH 2 H H 0 04 7 H CH 3 (CH 2)3 H H O O 1 8 H C 6 Hs H H 0 05 9 H Cl H H -0 07 10 H H H CH 3 0 0066 25 11 H CH 3 H CH 3 0 014 12 H H H C 2 Hs -0 0033 13 H H H CH 3 (CH 2)2 0 004 14 H H H CH 3 (CH 2)3 0 007 15 H H H Cl 0 05 30 16 H H H CH 30 0 07 17 CH 3 H H H 0 2 DSCG -0 6 >> 30 The following examples are provided solely for the purpose of illustrating preparation of the starting materials and compounds of the present invention and 35 are not to be construed as limitations of the invention All temperatures referred to below are in degrees Centigrade "Skellysolve B" is a petroleum ether fraction of b.p 60-68 C consisting essentially of n-hexane (trade name of Skelly Oil Co).

Preparation of Starting Materials A 2-Aminopyridines (general formula VII) 40 Preparation Al: 2-Amino-5-ethylpyridine a Benzyl ( 5-Ethyl-2-pyridyl)carbamate Diphenylphosphoryl azide ( 4 04 g, 14 7 mmoles) was added to a solution of 5ethylpyridine-2-carboxylic acid ( 2 22 g, 14 7 mmoles), triethylamine ( 1 485 g 14 7 mmoles), and benzyl alcohol ( 1 75 g, 16 17 mmoles) in 1,4-dioxane ( 23 5 ml), and 45 the mixture heated under reflux for one hour The 1,4-dioxane was removed under reduced pressure A solution of the residue in toluene was washed successively with water, aqueous sodium bicarbonate, and brine, and was then dried over sodium sulfate The toluene was removed and the residue recrystallized from 2propanol to 1,596,476 give benzyl ( 5-ethyl-2-pyridyl)carbamate (l 9 g, 50 5 %), m p 125-127 An analytical sample had m p 127-130 .

Anal Calcd for C 1 s H 16 N 202: C, 70 29; H, 6 29; N, 10 93.

Found: C, 70 01; H, 6 32; N, 10 72.

b 2-Amino-5-ethylpyridine 5 A suspension of benzyl ( 5-ethyl-2-pyridyl)carbamate ( 1 9 g, 7 43 mmoles) and % palladium-on-carbon ( 0 4 g) in ethanol ( 100 ml) was shaken with hydrogen at a pressure of 3 5 kg /cm 2 for 2 hours The catalyst was removed by filtration and the filtrate concentrated to yield 2-amino-5-ethylpyridine ( 0 9 g, 99 4 %) as a colorless oil 10 Preparation A 2: 2-Amino-5-n-butylpyridine a Benzyl ( 5-n-Butyl-2-pyridyl)carbamate Diphenylphosphoryl azide ( 1 5 g, 5 58 mmoles) was added to a solution of 5-nbutylpyridine-2-carboxylic acid ( 1 0 g, 5 58 mmoles), triethylamine ( 0 565 g, 5 58 mmoles), and benzyl alcohol ( 0 663 g, 6 12 mmoles) in 1,4-dioxane ( 9 0 ml) at 25 15 The stirred solution was heated until an exothermic reaction began When the exothermic reaction had subsided, the solution was heated under reflux for 1 5 hours The reaction mixture was concentrated and the residue dissolved in toluene.

This solution -was washed successively with water, 10 % aqueous sodium bicarbonate, and brine, and then dried over sodium sulfate The solution was 20 concentrated and the residue recrystallized from 2-propanol to give the title compound ( 0 91 g, 57 %), m p 142-143 .

Anal Calcd for C,7 H 20 N 202: C, 71 80; H, 7 09; N, 9 85.

Found: C, 71 72; H, 6 85; N, 9 87.

b 2-Amino-5-n-butylpyridine 25 A mixture of benzyl ( 5-n-butyl-2-pyridyl)carbamate ( 6 5 g 22 86 mmoles) and % palladium on carbon ( 2 7 g) in ethanol ( 400 ml) was shaken at room temperature for 2 hours in an atmosphere of hydrogen at an initial pressure of 3 52 kg./cm 2 The mixture was filtered and the filtrate reduced to dryness to leave 2amino-5-n-butylpyridine ( 3 42 g, 99 7 %), m p 30 33 (lit m p 35-36 in Helv 30 Chim Acta, 39, 505 ( 1956).

Preparation A 3: 2-Amino-5-phenylpyridine A solution of 2-chloro-5-phenylpyridine ( 4 0 g, 0 021 mole) in dry diethyl ether ( 160 ml) was added dropwise to a solution of sodium ( 3 39 g, 0 15 gatom) in liquid ammonia ( 160 ml) containing ferrous nitrate hexahydrate ( 0 095 g) The resulting 35 suspension was allowed to reflux for 4 hours Ammonium chloride was added and the ammonia allowed to evaporate The residue was treated with 5 % aqueous sodium hydroxide ( 5 ml) The mixture was filtered The aqueous layer was extracted with ether ( 2 x 100 ml) The combined ethereal layers were washed with brine and dried over sodium sulfate The solution was concentrated and the residue 40 recrystallized from methylcyclohexane The product was triturated with chloroform ( 100 ml) The mixture was filtered and the filtrate evaporated to give 2amino-5-phenylpyridine ( 1 3 g, 36 %), m p 133-135 (lit m p 133 in Chem Ber, 91, 247 ( 1958).

Preparation A 4: 2-amino-3,5-dimethylpyridine 45 Ferrous nitrate hexahydrate ( 60 mg) followed by sodium ( 4 5 g, 0 196 gatom) were added to liquid ammonia To this mixture was added a solution of 3,5dimethylpyridine ( 10 0 g, 0 093 mole) in N,N-dimethylaniline ( 21 ml) over a period of 5 minutes The ammonia was allowed to evaporate and the residue heated under nitrogen by means of an oil bath maintained at 180 for 18 hours The cooled 50 residue was treated with ice ( 50 g) followed by 2 N sodium hydroxide ( 50 ml) The mixture was triturated for 2 hours and then filtered The collected solid was washed with boiling toluene ( 2 x 100 ml) The toluene layer was separated from the combined filtrate and washings, concentrated to about 50 ml and extracted with 5 % aqueous acetic acid ( 5 x 20 ml) The combined extracts were filtered and 55 reduced to dryness The residue was recrystallized from methylcyclohexane to give 2-amino-3,5-dimethylpyridine acetate ( 4 9 g, 29 %), m p 85-95 .

The acetate ( 2 5 g, 1 37 mmoles) was briefly suspended in IN sodium 1,596,476 hydroxide ( 50 ml) The mixture was extracted with methylene chloride The extract was washed with water, dried, and concentrated to give 2-amino-3, 5dimethylpyridine as an oil.

Preparation A 5: 2-Amino-3-n-propylpyridine The title compound was prepared by the direct amination of 3-n 5 propylpyridine by a method similar to that described for the preparation of 2amino-3-ethylpyridine ' The initial mixture of 2-amino-3-n-propylpyridine and 2amino-5-n-propylpyridine was separated by high pressure liquid chromatography.

The 2-amino-3-n-propylpyridine was recrystallized from n-pentane to give material with m p 25-27 10 B Carboxamide Intermediates (general formula III) Preparation B I: 4-Oxo-4 H-pyridoll,2-alpyrimidine-3-carboxamide A steel bomb containing ethyl 4-oxo-4 H-pyridol 1,2-alpyrimidine-3carboxylate ( 14 0 g, 0 064 mole) and liquid ammonia (ca 55 ml) was heated on a steam bath for 2 hours and then stored at 25 for 18 hours The ammonia was 15 removed to leave a solid which was recrystallized from 2-methoxyethanol to give the title compound ( 4 2 g, 34 6 %), m p 266 268 (lit m p 264-268 in J Chem.

Soc (C), 2735 ( 1971).

Preparation B 2: 7-Chloro-4-oxo-4 H-pyridoll,2-alpyrimidine-3-carboxamide A suspension of ethyl 7-chloro-4-oxo-4 H-pyridol 1,2-alpyrimidine-3 20 carboxylate ( 9 7 g, 0 038 mole) in ammonium hydroxide ( 75 ml, sp gr 0 9) was triturated at room temperature for 18 hours The mixture was filtered and the collected solid retriturated at room temperature in fresh ammonium hydroxide ( 100 ml, sp gr 0 9) for a further 18 hours The solid material was collected by filtration, washed with cold water and dried to give the title compound ( 7 7 g, 90 %) 25 m.p 281-285 A small sample was recrystallized from 2-methoxyethanol to give analytical material, m p 285-287 .

Anal Calcd for Cg HC 1 N 302: C, 48 34; H, 2 70; Cl, 15 86; N, 18 79.

Found: C, 48 54; H, 2 73; C 1, 15 46; N, 19 10.

C Nitriles (general formula II) 30 Preparation C 1: 4-Oxo-4 H-pyridol 1,2-alpyrimidine-3-carbonitrile A mixture of 4-oxo-4 H-pyridoll,2-alpyrimidine-3-carboxamide ( 3 6 g, 0 019 mole) and phosphorus oxychloride ( 50 ml) was heated under reflux for 2 hours.

The mixture was concentrated and the solid residue partitioned between methylene chloride and aqueous sodium carbonate The methylene chloride layer was washed 35 with water; dried, and'concentrated The residue was recrystallized from toluene to give the title compound ( 2 5 g, 76 8 %), m p 219-221 Recrystallization from ethanol gave analytical material, m p 219-220 (lit m p 208 in J Amer Chem.

Soc, 80, 3066 ( 1958).

Preparation C 2: 7-Chloro-4-oxo-4 H-pyridol 1,2-alpyrimidine-3carbonitrile 40 A suspension of 7 chloro 4 oxo 4 H pyridol 1,2 alpyrimidine 3 carboxamide ( 7 55 g, 33 8 moles) in phosphorus oxychloride ( 200 ml) was heated under reflux for 3 5 hours The solution was concentrated A solution of the residual solid in methylene chloride was added to ice water The methylene chloride layer was concentrated and the residue recrystallized from 2 45 methoxymethanol to give the title compound ( 4 0 g, 57 6 %), m p 239-241 .

Anal Calcd for Cg H 4 C 1 N 30: C, 52 57; H, 1 96; Cl, 17 25; N, 20 44.

Found: C, 52 52; H, 2 08; Cl, 16 60; N, 20 32.

D Acrylates (general formula VI) Preparation Dl: Ethyl 2-Cyano-3-( 5-methyl-2-pyridylamino)acrylate 50 A mixture of 2 amino 5 methylpyridine ( 5 0 g, 46 2 mmoles) and ethyl ethoxymethylenecyanoacetate ( 7 82 g, 46 2 mmoles) was heated by means of an oil bath maintained at 100 for 15 minutes The mixture was cooled and the resultant solid recrystallized from acetonitrile to give the title compound ( 5 4 g, 5 O 51 '), m p.

170-171 5 55 Anal Calcd, for C,2 H 13 N 302: C, 62 32; H, 5 67; N, 18 17.

Found: C, 62 44; H, 5 74; N, 18 05.

r 6 1,596,476 Preparation D 2: Ethyl 2-Cyano-3-( 5-ethyl-2-pyridylamino)acrylate The title compound (m p 155-156 , 25 4 % yield) was prepared from 2 amino 5 ethylpyridine and ethyl ethoxymethylenecyanoacetate in a manner similar to that described for the preparation of ethyl 2 cyano 3 ( 5 methyl 2 pyridylamino)acrylate in Preparation Dl 5 Anal Calcd for C 13 Hls N 3 02: C, 63 66; H, 6 16; N, 17 13.

Found: C, 63 54; H, 6 09; N, 17 02.

Preparation D 3: Ethyl 2-Cyano-3-( 5-n-butyl-2-pyridylamino)acrylate A solution of 2 amino 5 N butylpyridine ( 3 72 g, 23 43 mmoles) and ethyl ethoxymethylenecyanoacetate ( 3 96 g, 23 43 mmoles) in toluene was heated 10 for 10 minutes by means of an oil bath maintained at 100 The solution was cooled and treated with Skellysolve B ( 200 ml) The mixture was triturated for 18 hours at room temperature and then filtered The collected title compound ( 4 3 g, 67 2 %) had m p 69-73 .

15 Preparation D 4: Ethyl 2-Cyano-3-( 5-phenyl-2-pyridylamino)acrylate A mixture of 2 amino 5 phenylpyridine ( 1 19 g, 6 99 mmoles) and ethyl ethoxymethylenecyanoacetate ( 1 18 g, 6 99 mmoles) was fused at an oil bath temperature of 100 for 15 minutes The product was recrystallized from toluene to give the title compound ( 1 3 g), m p 126-134 An additional crop of product ( 0 3 g); m p 119-126 was obtained from the mother liquors Total yield of product, 20 1.6 g ( 78 %).

Preparation D 5: Ethyl 2-Cyano-3-( 3-methyl-2-pyridylamino)acrylate A solution of 2 amino 3 methylpyridine ( 5 0 g, 0 0462 mole) and ethyl ethoxymethylenecycanoacetate ( 7 82 g, 0 0462 mole) in toluene ( 4 ml) was heated for 15 minutes by means of an oil bath maintained at 100 The solution was cooled 25 and the title compound ( 9 1 g, 85 %) collected by filtration The product, m p.

139-143 , was recrystallized from 2-propanol'to give an analytical sample, m p.

144-146 .

Anal Calcd for C,2 H 3 N 302: C, 62 32; H, 5 67; N, 18 17.

Found: C, 61 87; H, 5 63; N, 18 42 30 Preparation D 6: Ethyl 2-Cyano-3-( 3,5-dimethyl-2-pyridylamino)acrylate The title compound ( 79 % yield), m p 156-159 from methylcyclohexane, was prepared in a manner similar to that described for the preparation of ethyl 2 cyano 3 ( 3 methyl 2 pyridylamino)acrylate in Preparation D 5.

Anal Calcd for C 13 H 1 s N 302: C, 63 66; H, 6 16; N, 17 13 35 Found: C, 63 94; H, 6 24; N, 16 78.

Preparation D 7: Ethyl 2-Cyano-3-( 3-ethyl-2-pyridylamino)acrylate A solution of 2-amino-3-ethylpyridine ( 13 0 g, 0 1063 mole) and ethyl ethoxymethylenecyanoacetate ( 18 0 g, 0 1063 mole) in toluene ( 50 ml) was heated on a steam bath for 20 minutes The solution was cooled and the mixture diluted 40 with Skellysolve B The mixture was filtered to give 19 0 g of the title compound, m.p 122-125 The filtrate was reduced to dryness and the residue recrystallized from cyclohexane to give a further 7 0 g of product, m p 122-125 (total yield 99.6 %) A portion of the second crop was recrystallized twice from methanol to give analytical material, m p123-125 45 Anal Calcd for C,3 Hs N 3 002: C, 63 66; H, 6 16; N, 17 13.

Found: C, 63 49; H, 6 18; N, 17 13.

Preparation D 8: Ethyl 2-Cyano-3-( 3-n-propyl-2-pyridylamino)acrylate The title compound (m p 99-100 , 60 % yield) was prepared from 2 amino 3 N propylpyridine and ethyl ethoxymethylenecyanoacetate in a manner similar 50 to that described for the preparation of ethyl 2 cyano 3 ( 5 N butyl 2 pyridylamino) acrylate in Preparation D 3.

Anal Calcd for C,4 HN 302: C, 64 84; H, 6 61; N, 16 21.

Found: C, 64 83; H, 6 61; N, 16 07.

1,596,476 Preparation D 9: Ethyl 2-Cyano-3-( 3-n-butyl-2-pyridylamino)acrylate The title compound (m p 98 5-99 5 , 84 % yield) was prepared from 2amino3-n-butylpyridine and ethyl ethoxymethylenecyanoacetate in a manner similar to that described for the preparation of ethyl 2 cyano 3 ( 5 N butyl 2 pyridylamino)acrylate in Preparation D 3 5 Anal Calcd for Cs H 19 g N 302: C, 65 91: H, 7 01; N, 15 37.

Found: C, 65 73; H, 6 95; N, 15 32.

Preparation DI 0: Ethyl 2-Cyano-3-( 3-chloro-2-pyridylamino)acrylate The title compound (m p 139 5-141 5 , 44 % yield) was prepared from 2 amino 3 chloropyridine and ethyl ethoxymethylenecycanoacetate in a manner 10 similar to that described for the preparation of ethyl 2 cyano 3 -( 5 N butyl 2 pyridylamino)acrylate in Preparation D 3.

Anal Calcd for C Ho CIN 302: C, 52 50; H, 4 01; Cl, 14 09: N, 16 7 Found: C, 52 22; H, 3 98; Cl, 13 93; N, 17 0.

Preparation DII: Ethyl 2-Cyano-3-( 3-methoxy-2-methoxy-2-pyridylamino) 15 acrylate The title compound (m p 187-188 , 43 % yield) was prepared from 2 amino 3 methoxypyridine and ethyl ethoxymethylenecyanoacetate in a manner similar to that described for the preparation of ethyl 2 cyano 3 ( 5 N butyl 2 pyridylamino)acrylate in Preparation D 3 20 Anal Calcd for C 12 H 13 N 303: C, 58 29; H, 5 30; N, 17 00.

Found: C, 58 01; H, 5 34; N, 17 14.

Example I

3-( 1 H-Tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one (via nitrile II) 25 A stirred mixture of 4 oxo 4 H pyridoll,2-alpyrimidine 3 carbonitrile ( 2.17 g, 0 0127 mole), sodium azide ( 0 911 g, 0 014 mole), and ammonium chloride ( 0.75 g, 0 014 mole) in N,N dimethylformamide ( 20 ml) was heated by means of an oil bath maintained at 120 for 19 hours The solvent was removed and the residue treated with hot aqueous sodium bicarbonate The mixture was filtered 30 The filtrate was acidified with acetic acid The precipitate was collected and recrystallized from acetic acid to give the title compound ( 0 52 g, 19 %, ) m p 308309 (decomp) Recrystallization from acetic acid with charcoal treatment gave analytical material, m p 311-312 (decomp).

Anal Calcd for Cg H 6 N 60: C, 50 46; H, 2 82; N, 39 24 35 Found: C, 50 16; H, 2 81; N, 39 18.

Example 2

3-( 1 H-Tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one (via acrylate VI) Aluminum chloride ( 0 74 g, 5 56 mmoles) was carefully added to 40 tetrahydrofuran ( 33 ml) at -20 Sodium azide ( 1 08 g, 16 6 mmoles) was then added and the mixture heated under reflux for 30 minutes After the addition of ethyl 2 cyano 3 ( 2 pyridylamino)acrylate ( 1 0 g, 4 6 mmoles) the mixture was again heated under reflux for 18 hours The mixture was cooled in an ice bath, treated with water ( 170 ml) and acidified to p H 2 with 6 NV hydrochloric acid The 45 resulting suspension was stirred with cooling for 2 hours and then filtered The collected solid was recrystallized from N,N-dimethylformamide to give the title compound ( 0 38 g, 38 5 %), m p 308-309 (decomp) Example 3

3-( 1 H-tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one 50 (via 2-aminopyridine+ethoxymethylenecyanoacetate+Al(N 3)3 without isolation of intermediates) Aluminum chloride ( 1 73 g, 12 96 mmoles) was added to tetrahydrofuran ( 45 ml.) at -20 Sodium azide ( 2 52 g, 38 71 mmoles) was then added and the mixture heated under reflux for 40 minutes To this mixture was added 2aminopyridine ( 1 0 55 g., 10 62 mmoles) and ethyl ethoxymethylenecycanoacetate ( 1 8 g 10 62 mmoles).

1,596,476 The mixture was heated under reflux for 18 hours The mixture was concentrated and the residue treated with water ( 50 ml) The mixture was acidified to p H 3 with 6 N hydrochloric acid The solid material was collected and suspended in 3 % aqueous sodium bicarbonate The mixture was heated under reflux for 5 minutes, filtered, and the filtrate acidified to p H 4 with 6 N hydrochloric acid The 5 precipitate was recrystallized from N,N-dimethylformamide to give the title compound ( 0 35 g, 15 4 %), m p 312-313 (decomp).

Example 4

7-Methyl-3-( 1 H-tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-oneIn a manner similar to that described for the preparation of 3-(l Htetrazol-5 10 yl)-4 H-pyridof 11,2-alpyrimidin-4-one in Example 2, the title compound was prepared from ethyl 2 cyano 3 ( 5 methyl 2 pyridylamino)acrylate The product ( 42 8 % yield) had m p 321-322 (decomp) after recrystallization from glacial acetic acid.

I 5 Anal Calcd for C 1 o Hs N 60: C, 52 63; H, 3 53; N, 36 83 15 Found: C, 52 26; H, 3 40; N, 36 47.

Example 5

8-Methyl-3-( 1 H-tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one The title compound ( 16 % yield, m p 307 with decomposition) was prepared from ethyl 2 cyano 3 ( 4 methyl 2 pyridylamino)acrylate in a manner 20 similar to that described for the preparation of 3 (IH tetrazol 5 yl) 4 H pyridoll,2-alpyrimidin 4 one in Example 2.

Anal Calcd for C,1 o Hs N 0: C, 52 63; H, 3 53; N, 36 83.

Found: C, 52 57; H, 3 27; N, 36 92 (corrected for 2 7 % H 20) 25 Preparation of the starting material acrylate is disclosed in J Hetercycl Chem.

8, 759 ( 1971).

Example 6

7-Ethyl-3-(I H-tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one The title compound ( 28 % yield, m p 289-290 5 with decomposition) was 30 prepared from ethyl 2 cyano 3 ( 5 ethyl 2 pyridylamino)acrylate in a manner similar to that described for the preparation of 3 (IH tetrazol 5 yl) 4 H pyridoll,2 alpyrimidin 4 one in Example 2.

Anal Calcd for C Ho N 60: C, 54 54; H, 4 16; N, 34 70.

Found: C, 54 31; H, 4 09; N, 34 52 35 Example 7

7-n-Butyl-3-(l H-tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one Aluminum chloride ( 0 89 g, 6 67 mmoles was carefully added to cold (-30 ) tetrahydrofuran ( 42 ml) Sodium azide ( 1 3 g, 20 0 mmoles was then added and the mixture heated at reflux for 40 minutesEthyl 2 cyano 3 ( 5 N butyl 2 40 pyridylamino)acrylate ( 1 50 g, 5 49 mmoles) was added and the mixture heated under reflux for 18 hours The cooled mixture was concentrated and the residue treated with ice water ( 50 ml) The mixture was acidified to p H 3 with 6 N hydrochloric acid The mixture was filtered and the collected solid treated with boiling 3 % aqueous sodium bicarbonate for 10 minutes The mixture was filtered 45 and the filtrate acidified to p H 4 with 6 N hydrochloric acid The precipitate was recrystallized from N,N-dimethylformamide to give the title compound ( 0 45 g, 30.4 %), m p 284-285 (decomp).

Anal Calcd for C,13 H 14 NO: C, 57 76; H, 5 22: N, 31 10.

Found: C, 57 37; H, 5 23; N, 31 21 50 Example 8

7-Phenyl-3-( 1 H-tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one In a manner similar to that described for the preparation of 7 N butyl 3 (I H tetrazol 5 yl) 4 H pyridol 1,2 alpyrimidin 4 one in Example 7, the 1,596,476 title compound (m p 308-309 decomp) was prepared in 31 % yield from ethyl 2 cyano 3 ( 5 phenyl 2 pyridylamino)acrylate.

Anal Calcd for C 1 s H 1 o N 60: C, 62 06; H, 3 47; N, 28 95.

Found: C, 61 93; H, 3 37; N, 28 67.

Example 9 5

7-Chloro-3-( 1 H-tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one Aluminum chloride ( 0 72 g, 5 45 mmoles) was carefully added to cold (-30 ) tetrahydrofuran ( 29 ml) Sodium azide ( 1 06 g, 16 27 mmoles) was then added and the mixture heated under reflux for 30 minutes 7 Chloro 4 oxo 4 H pyridot 1,2 alpyrimidine 3 carbonitrile ( 1 0 g, 4 47 mmoles) was added and the 10 mixture heated under reflux for 18 hours The cooled mixture was poured onto 500 ml of ice water and the resulting mixture acidified to p H 2 with 6 N hydrochloric acid The precipitate was collected and recrystallized from N,N dimethylformamide to give the title compound ( 0 55 g, 49 5 %), m p 300301 (decomp) 15 Anal Calcd for Cg Hs CIN 6 O: C, 43 47; H, 2 03; Cl, 14 26; N, 33 80.

Found: C, 43 63; H, 2 19; Cl, 13 74; N, 33 62.

Example 10

9-Methyl-3-( 1 H-tetrazol-5-yl)-4 H-pyridol 1,2-al pyrimidin-4-one Aluminum chloride ( 3 51 g, 0 0263 mole) was added to cold (-30 ) 20 tetrahydrofuran ( 180 ml) Sodium azide ( 5 12 g, 0 0788 mole) was added and the mixture heated under reflux for 30 minutes The mixture was cooled to 5 Ethyl 2 cyano 3 ( 3 methyl 2 pyridylamino)acrylate ( 5 0 g, 0 0216 mole) was added and the mixture heated under reflux for 18 hours The tetrahydrofuran was removed under reduced pressure The residue was treated with ice water ( 100 ml) 25 and acidified to p H 3 with 6 N hydrochloric acid The mixture was filtered and the collected solid recrystallized from N,N dimethylformamide to give the title compound ( 2 5 g, 50 7 %), m p 310-311 (decomp).

Anal Calcd for Co H 8 NO: C, 52 63; H, 3 53; N, 36 83.

Found: C, 52 03; H, 3 51; N, 37 08 30 Example 11

7,9-Dimethyl-3-( IH-tetrazol-5-yl)-4 H-pyridol 1,2-al pyrimidin-4-one The title compound ( 37 6 % yield), m p 308-309 (decomp) from 2methoxyethanol, was prepared in a manner similar to that described for the preparation of 9 methyl 3 (IH tetrazol 5 yl) 4 H pyridoll,2 35 alpyrimidin 4 one in Example 10.

Anal Calcd for C,H,o NO 60: C, 54 54; H, 4 16; N, 34 70.

Found: C, 54 09; H, 4 10; N, 35 29.

Example 12

9-Ethyl-3-( 1 H-tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one 40 Ethyl 2 cyano 3 ( 3 ethyl 2 pyridylamino)acrylate ( 10 0 g, 0 0408 mole) was added to a stirred mixture of aluminum azide in tetrahydrofuran at O .

The aluminum azide had been prepared in situ in the usual manner from aluminum chloride ( 6 5 g, 0 0488 mole) and sodium azide ( 9 5 g, 0 1464 mole) in tetrahydrofuran ( 100 ml) The mixture was stirred at 0 for 15 minutes and then 45 heated under reflux for 19 hours The mixture was cooled, diluted with water, and acidified with concentrated hydrochloric acid ( 20 ml) The mixture was filtered to give the title compound ( 2 7 g, 27 %), m p 285-288 The product was recrystallized from N,N-dimethylformamide with charcoal treatment to give analytical material, m p 288-290 (decomp).

Anal Calcd for C 1 Ho N 6 O: C, 54 54; H, 4 16: N, 34 70.

Found: C, 54 70; H, 4 17: N, 35 27.

Example 13

9-n-Propyl-3-( 1 H-tetrazol-5-yl)-4 H-pyridol I,2-alpyrimidin-4-one The title compound (m p 269-272 with decomposition, 27 6 % yield) was 55 1,596,476 prepared from ethyl 2-cyano-3-( 3-n-propyl-2-pyridylamino)acrylate in a manner similar to that described for the preparation of 3 (IH tetrazol 5 yl) 4 H pyridoll,2 alpyrimidin 4 one in Example 2.

Anal Calcd for C 12 H,2 N 80: C, 56 24; H, 4 72; N, 32 80.

Found: C, 56 15; H, 4 64; N, 32 99 5 Example 14

9-n-Butyl-3-( I H-tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one The title compound (m p 255 5-257 5 with decomposition, 30 % yield) was prepared from ethyl 2 cyano 3 ( 3 N butyl 2 pyridylamino) acrylate in a manner similar to that described for the preparation of 3 -(IH tetrazol 5 yl) 10 4 H pyridoll,2 alpyrimidin 4 one in Example 2:

Anal Calcd for C 13 H 14 NO 0: C, 57 76; H, 5 22; N, 31 10.

Found: C, 57 71; H, 5 32; N, 31 07.

Example 15

9-Chloro-3-(l H-tetrazol-5-yl)-4 H-pyridol 1,2-al pyrimidin-4-one 15 The title compound (m p 313-315 with decomposition, 44 % yield) was prepared from ethyl 2 cyano 3 ( 3 chloro 2 pyridylamino)acrylate in a manner similar to that described for the preparation of 3 (IH tetrazol 5 yl)4 H pyridol 1,2 alpyrimidin 4 one in Example 2.

Example 16 20

9-Methoxy-3-(IH-tetraz 161-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one Aluminum chloride ( 0 79 g, 5 94 m moles) was added to cooled tetrahydrofuran ( 35 ml) Sodium azide ( 1 16 g, 17 82 m moles) was added and the mixture heated under reflux for 30 minutes After the addition of ethyl 2 cyano 3 ( 3 methoxy 2 pyridylamino)acrylate ( 1 21 g, 4 89 m moles) the mixture was 25 again heated under reflux for 18 hours The mixture was cooled and treated with 6 N hydrochloric acid and water ( 100 ml) The precipitate was extracted with 3 % aqueous sodium bicarbonate The extract was filtered while hot The filtrate was cooled and acidified with hydrochloric acid The precipitate was collected and dried to give the intermediate ethyl 2( 1 Htetrazol 5 yl) 3 -( 3 methoxy 30 2 pyridylamino)acrylate ( 0 21 g), m p 275-278 with decomposition.

Recrystallization of this intermediate from N,N dimethylformamide gave the title compound ( 95 mg, 8 %), m p 298-299 with decomposition.

Example 17

6-Methyl-3-( 1 H-tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one 35 The title compound (m p 295-296 with decomposition, 21 % yield) was prepared from 6 methyl 4 oxo 4 H pyridoll,2 alpyrimidine 3 carbonitrile 2 in a manner similar to that described for the preparation of 7 chloro 3 (IH tetrazol 5 yl) 4 H pyridoll,2 alpyrimidin 4 one in Example 9 40

Anal Calcd for C,1 o HN O O: C, 52 63; H, 3 53; N, 36 83.

Found: C, 52 62; H, 3 40; N, 36 63.

Ref No 2 I Hermecz et al, J Chem Soc, Perkin I 789 ( 1977).

Example 18

Following the general procedures of Examples 1-12, the following 45 compounds may be prepared by use of the appropriate 2-aminopyridine starting material.

1,596,476 1,596,476 R 3 R COH NO, a NH, H H CH, NO, H H H cl H H H H H H H H H H C^HCH, p-chlorophenyl H Br Br H H H H OH CH 35 O H n-CH 7 CH,=CHCH, CH-=CCH, (CH 3)2 CH (C Hz)2 C (CH,),CHCH 2 CAHCH(CH 2) H H H H H H H H cl H cl H Br H CH, H H H cl cl H H H H H H H H H H H H CH 3 H H H H H H H H H H H H H H H H H cl H CH, H H H H H H H H H H H H H H H CH,0 CH, cl H CH,, CH 3 F CH, CH, CH 3 H CH, Br CH, CH, H H H H H H C HOC H 2 C H 2 (C H 3)2 C H C 2 H, CH, b OH HOCH 2 CH 2 Cr H p-c hlorop henyl o-methylphenyl o-ethylphenyl m-methoxyphenyl p-ethoxyphenyl o-bromophenyl 3-ch 1 o ro-4-methylp he nyl 3,4-dimethoxyphenyl H H H H Br H H H H H H NO, H H H H H H H (CHI)CHCH, CAHCH(CH,) (CH 3)3 C n-CH 11 H B r CH, cl CH 3 B r CH 3 CH, B r Cl B r H cl CAH O n-C 23 H, (CH,),CHO H H H H H H H H H H H H H H H H H H H H H H H CH,0 H H CH,0 H Br CH, H H H H H H H H H H H H H H H H b OH H CH 3 H H H H NO, CH, NO, CH, NO, CH, CH, H H H 23 1,596,476 2 R' i H H H H H H H H H H H H n-CH 90 H (CH,),CO H CHCH,(CH,)CHO H (CH,),CHCH,0 H CH 2 =CH-CH,0 H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H C H a Lz CH 2 O COH a NH 2 CHS CHS c CHNH CCAHNH (CH:1)2 N CF, CH,=CHCH, CH,=CH CH=C CH=CCH 2 CH,=CHO H H H H H H H H H H H H H H 1 5 o H CH,,OCH 20 H CH,OCH,CH 20 H / O H H H H <.,CH>'/cv, H H H H H 1 ' '-' -DC H 2) 3 R' R 2 R 3 R 4 H H H H 0 CH 2)5 \& 9 H 2)5 H H H H H H H H H H H H H H H H H H H H H H H H H COOCH, H COOC 2 Hs H CHSO H C:Hs SO H CH 3 CO H C 2 Hs CO H CH 3 COO H C 2 H 5 COO H OCHCH 2 OH H OCH 2-CH-CH 2 OH OHH H H H H H CH 30 H C Hs O O H CH 35 H CF 3 H c CHNH H ' C 2 Hs NH H (CH:)2 N H H H H H L> CH 2 H H H H H H H H H H H H H H OCH 2 CH-CH 2 OCH 3 I OH OCH 2 C 6 H.

OCH 2 CH 2 CH 20 H H H H H H H H Br H H a: prepared from corresponding nitro-substituted compound by catalytic reduction b: prepared from corresponding protected-hydroxy compound (e g.

benzyloxy or methoxy) via removal of protecting group (e g hydrogenolysis for benzyloxy or treatment with a dealkylating agent (such as hydrobromic acid) for methoxy) c: prepared by alkylation of corresponding amino-substituted compound Example 19

9-Methyl-3-( 1 H-tetrazol-5-yl)-4 H-pyridolI,2-alpyrimidin-4-one Sodium Salt 1.0 N Sodium hydroxide ( 26 5 ml) was added dropwise to a stirred mixture of 9 methyl 3 (IH tetrazol 5 yl) 4 H pyridoll,2 alpyrimidin 4 one 1.596476 ( 6.0 g, 0 02625 mole) in water ( 150 ml) The mixture was diluted with water to a volume of about 300 ml and was then heated to a temperature of 50 during two minutes The mixture was filtered and the water removed from the filtrate by lyophilization The residue was recrystallized from water:ethanol to give the title compound ( 5 4 g), m p 346 (decomp) Elemental analyses were performed on the 5 product after it had been stored at 22 for 66 hours at a relative humidity of 5055/%.

Anal Calcd for Co H Na N 6 O: C, 48 01; H, 2 82.

Found: C, 47 91; H, 2 78 (corrected for 9 01 % H 20) 10 Replacement of the 9 methyl 3 (I H tetrazol 5 yl) 4 H pyridoll,2 alpyrimidin 4 one in the above procedure with an equimolar weight of the other 3 ( 1 H tetrazol 5 yl) 4 H pyridoll,2 alpyrimidin 4 one compounds prepared in Examples I-13 above gives the corresponding sodium salts for each of the indicated compounds 15 Replacement of the sodium hydroxide in the above procedure with other bases, e g KOH, Ca(OH)2, Mg(OH)2 or NH 4 OH gives the corresponding base addition salts.

Reaction of the 3 ( 1 H tetrazol 5 yl) 4 H pyridoll,2 alpyrimidin 4 one compounds of Examples 1-13 with an equivalent weight of ethanolamine, 20 ethylenediamine, diethanolamine, triethanolamine or tris(hydroxymethyl)aminomethane gives the corresponding amine salts for each of the indicated compounds.

The 3 ( 1 H tetrazol 5 yl) 4 H pyridol 1,2 alpyrimidin 4 one compounds of Examples 1-13 may be converted to their acid addition salts by 25 addition of a stoichiometric equivalent of a suitable organic or inorganic acid, e g.

HCI, H Br, HI, H 3 PO, or CH 3 COOH.

Claims

WHAT WE CLAIM IS:-

1 A compound of the general formula:

N N H 30 wherein R', R 2, R 3 and R 4 which may be the same or different are each hydrogen, halogen, (lower)alkyl, cyclo(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, (lower)alkenyl, (lower)alkynyl, (lower)alkoxy, (lower)alkoxy(lower)alkyl, -O(lower)alkenyl, (c H 2)m mc HC 2)n 35 in which m is 0 or an integer from I to 6 and N is an integer from 2 to 7, -OCH 2 (CH 2)x O(CH 2),CH 3 in which x andy are each independently 0 or an integer from I to 6, CF 3, hydroxy, hydroxymethyl, (lower)alkylthio, amino, nitro, -N (CF 2 40 in which r is 4 or 5, (lower)alkylamino, di(lower)alkylamino, carboxyl, -CO 2-(lower)alkyl, phenyl, phenyl substituted by one or two (lower)alkyl, (lower)alkoxy or halogen radicals, 1,596,476 benzyl, (lower)alkylsulfinyl, Re-CO in which RI is (lower)alkyl, Rc COO in which RC is (lower)alkyl, -O(CH 2)k OH in which k is an integer from 2 to 6, -OCH 2-CH-CH 2 OH, OH OH -OCH 2-CH-CH 2 OCH 3 or -OCH 2 Cs Hs, OH OH or R 2 and R 3 or R 3 and R 4 when taken together are methylenedioxy or in which N is 3, 4 or 5.

2 A compound of the general formula:

R 3 N H wherein R', R 2 and R 3 are as defined in claim I except that it is any two of R', R 2 and R 3 at positions 7 and 8 or 8 and 9 of the pyridoll,2-alpyrimidine ring system which when taken together represent methylenedioxy or in which N is 3, 4 or 5.

3 A compound of the general formula:

N H I' ' wherein RI and R 2 are as defined in claim I except that it is R' and R 2 when taken together at positions 7 and 8 or 8 and 9 of the pyridol 1,2-alpyrimidine ring system which represent methylenedioxy or \-Jc H 2 I n in which N is 3, 4 or 5.

4 A compound of the general formula:

H N I' '' wherein RI and R 2 are as defined in claim I except that it is R 1 and R 2 when taken together at positions 8 and 9 of the pyridol l,2-alpyrimidine ring system which represent methylenedioxy or in which N is 3, 4 or 5.

1.596476 R 1 A compound of the general formula:

N 0 R 2 I/ N H wherein R' and R 2 are as defined in claim 1.

6 A compound of the general formula:

o H wherein R' is as defined in claim 1.

7 A compound as claimed in any one of the preceding claims wherein R', R 2, R 3 and/or R 4 are each independently hydrogen, (lower)alkyl, (lower) alkenyl, (lower)-alkoxy, hydroxy, carboxy, (lower)alkylthio, halogen, CF 3, amino, (lower)alkylamino, di(lower) alkylamino, phenyl or benzyl 10 8 A compound as claimed in claim 7 wherein R', R 2, R 3 and/or R 4 are independently hydrogen, lower alkyl, lower alkoxy, halogen or phenyl.

9 A compound as claimed in claim 1 wherein R' and R 3 are independently hydrogen or lower alkyl and R 2 and R 4 are independently hydrogen, lower alkyl, lower alkoxy, halogen or phenyl 15 A compound as claimed in claim I wherein R 1 and R 3 are independently hydrogen or methyl, R 2 is hydrogen, methyl, ethyl, n-propyl, n-butyl, chloro or phenyl and R 4 is hydrogen, methyl, ethyl, n-propyl, n-butyl, chloro or methoxy.

11 9-Methyl-3-(l H-tetrazol-5-yl)-4 H-pyridol 1,2-alpyrimidin-4-one.

12 A compound as claimed in claim 1, other than the compound claimed in 20 claim 11, as specifically defined in the Examples.

13 A pharmaceutically acceptable salt of a compound as claimed in any one of the preceding claims.

14 A pharmaceutically acceptable salt as claimed in claim 13 which is a salt with hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, acetic, 25 lactic, citric, tartaric, oxalic, succinic, maleic, gluconic, ascorbic or ptoluenesulfonic acid.

A pharmaceutically acceptable salt as claimed in claim 13 which is a salt with ammonia, an organic amine or a metal salt containing sodium, potassium, calcium, magnesium, barium or aluminium cations 30 16 A process for the preparation of a compound as claimed in any one of the preceding claims, which comprises reacting a nitrile of the formula:

R 1 R N N wherein R', R 2, R 3 and/or R 4 when present are defined as in claims 1 to 11 with hydrazoic acid or an ammonium, substituted ammonium, sodium, lithiumrn or 35 aluminium azide in an inert organic solvent and if desired converting in a manner known per se the desired product to a pharmaceutically acceptable salt thereof.

17 A process as claimed in claim 16 wherein the reaction is carried out at an elevated temperature.

1,596,476 18 A process as claimed in claim 17 wherein the reaction is carried out at the reflux temperature of the solvent.

19 A process as claimed in any one of claims 16 to 18 wherein the nitrile of Formula II is reacted with aluminium azide in tetrahydrofuran.

20 A process as claimed in claim 19 wherein the aluminium azide is generated 5 in situ from the reaction of aluminium chloride and sodium azide.

21 A process as claimed in any one of claims 16 to 18 wherein the nitrile of Formula II is reacted with hydrazoic acid in an inert organic solvent.

22 A process as claimed in claim 21 wherein the solvent is benzene, xylene or toluene 10 23 A process as claimed in any one of claims 16 to 18 wherein the nitrile of Formula II is reacted with sodium azide and acetic acid in butanol.

24 A process as claimed in claim 16 substantially as hereinbefore described with reference to any one of Examples 1, 9, 17, 18 or 19.

25 A process for the preparation of a compound as claimed in any one of 15 claims I to 15, which comprises reacting a 2-amino-pyridine of the formula R R 2 2 R 3 /R 4 ll H R 2 R R H wherein R 1, R 2, R 3 and/or R 4 when present are defined as in claims I to 11 with ethyl ethoxymethylenecyanoacetate of the formula C 2 Hs CH=C(CN)CO 2 C 2 H 5 VIII 20 in the presence of aluminium azide in tetrahydrofuran to form the desired product in one step, or carrying out the reaction with ethyl ethoxymethylenecyanoacetate in the absence of aluminium azide, isolating the compound of the formula:

R 1 R 2 R 3 VI NHCH=C(CN)C 02 C 2 H 5 R 4 and treating said compound with aluminium azide in tetrahydrofuran; recovering 25 the desired product by acidification and, if desired, converting in a manner known per se the desired product to a pharmaceutically acceptable salt thereof.

26 A process as claimed in claim 25, wherein the compound of Formula VII is reacted with ethyl ethoxymethylenecyanoacetate in the presence of aluminium azide at the reflux temperature of tetrahydrofuran 30 27 A process as claimed in claim 26 wherein the aluminium azide is generated in situ from the reaction of sodium azide and aluminium chloride.

28 A process as claimed in claim 25 substantially as hereinbefore described with reference to any one of Examples 2 to 8, 10 to 16, 18 or 19.

29 A compound as claimed in any one of claims I to 15 whenever prepared by 35 a process as claimed in any one of claims 16 to 28.

A pharmaceutical composition for inhibiting or preventing the symptoms of an allergic reaction which comprises a compound as claimed in any one of claims I to 15 or claim 29 together with a pharmaceutically acceptable carrier or diluent 40 31 A composition as claimed in claim 30 which is in a form suitable for oral administration.

1,596,476 29 1,596,476 29 32 A method of inhibiting or preventing the symptoms of an allergic reaction in a non-human mammal which comprises administering to the mammal a prophylactically effective dose of a compound as claimed in any one of claims I to 15, or claim 29.

BOULT, WADE & TENNANT, Chartered Patent Agents, 34 Cursitor Street, London EC 4 A IPQ Printed for Her Majesty's Stationery Office, by the Courier Press, Leamington Spa, 1981 Published by The Patent Office, 25 Southampton Buildings, London, WC 2 A IAY, from which copies may be obtained.